Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Update on NUTRIVENTION-2 and NUTRIVENTION-3: high-fiber dietary intervention for MGUS and SMM

Urvi Shah • 6 Dec 2025
ASH 2025
Smoldering Myeloma
NUTRIVENTION-2 NUTRIVENTION-3

Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the ongoing NUTRIVENTION-2 (NCT06055894) and NUTRIVENTION-3 (NCT05640843) trials investigating the impact of a high-fiber dietary intervention on biomarkers of disease in participants with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). If you’re interested in getting in touch, please contact: shahnutrivention@mskcc.org. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Urvi Shah

NUTRIVENTION-5: a dietary intervention for NDMM with standard induction chemotherapy 3:18
NUTRIVENTION-5: a dietary intervention for NDMM with standard induction chemotherapy
Urvi Shah • 6 Dec 2025
The potential of non-drug interventions in SMM and MGUS: diet and lifestyle 5:11
The potential of non-drug interventions in SMM and MGUS: diet and lifestyle
Urvi Shah • 14 Mar 2025
Ongoing studies investigating dietary interventions to prevent myeloma: the NUTRIVENTION trials 1:48
Ongoing studies investigating dietary interventions to prevent myeloma: the NUTRIVENTION trials
Urvi Shah • 14 Mar 2025
Racial differences in the proportion of myeloma cases attributable to obesity 1:31
Racial differences in the proportion of myeloma cases attributable to obesity
Urvi Shah • 7 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Updates on current research exploring treatment strategies for high-risk smoldering myeloma 2:14
Updates on current research exploring treatment strategies for high-risk smoldering myeloma
Karthik Ramasamy • 15 Sep 2025
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment 4:27
Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
Claudio Cerchione • 18 Sep 2025
Performance of a novel prognostic index for multiple and smoldering myeloma 1:49
Performance of a novel prognostic index for multiple and smoldering myeloma
Claudio Cerchione • 18 Sep 2025
The content of VJHemOnc is intended for healthcare professionals